Technetium Tc-99m tilmanocept is a radiopharmaceutical diagnostic imaging agent indicated with or without scintigraphic imaging for lymphatic mapping and guiding sentinel lymph node biopsy. It is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone.
- Mechanism
- Curator reviewed
The mannose of the molecule acts as a ligand and guides the molecule to selectively bind to human mannose binding receptors (CD206) located on the surface of reticuloendothelial cells residing within lymph nodes, such as macrophages and dendritic cells. According to in vitro studies, technetium Tc 99m tilmanocept demonstrates selective binding to CD206 with a primary binding site affinity of Kd = 2.76 x 10^-11 M.
- Primary indication
- Indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component...Curator reviewed · 4 structured indications
- First approval
- United States, 2013
- Also known as
- Technetium (99mTc) tilmanocept · Technetium Tc 99m Tilmanocept · Technetium Tc99 tilmanocept
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with Technetium Tc-99m tilmanocept, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account